Comparison of Three Different A1 Adenosine Receptor Antagonists on Infarct Size and Multiple Cycle Ischemic Preconditioning in Anesthetized Dogs

Journal of Pharmacology and Experimental Therapeutics

Volumn 308, Issue 3, 2004, Pages 846-856

  Auchampach, John A ^a   Jin, Xiaowei ^b   Moore, Jeannine ^a   Wan, Tina C ^a   Kreckler, Laura M ^a   Ge, Zhi Dong ^a   Narayanan, Jayashree ^a   Whalley, Eric ^b   Kiesman, William ^b   Ticho, Barry ^b   Smits, Glenn ^b   Gross, Garrett J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIPROPYL 8 (4 SULFOPHENYL)XANTHINE; 1,3 DIPROPYL 8 [1 (4 PROPIONATE)BICYCLO[2.2.2]OCTYL]XANTHINE; 1,3 DIPROPYL 8 [4 [[(4 CYANOPHENYL)CARBAMOYLMETHYL]OXY]PHENYL]XANTHINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)BICYCLO[2.2.2]OCTAN 1 YL]PROPIONIC ACID; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; NAXIFYLLINE; UNCLASSIFIED DRUG; 1,3 DIPROPYL 8 (2 (5,6 EPOXY)NORBORNYL)XANTHINE; 1,3-DIPROPYL-8-(2-(5,6-EPOXY)NORBORNYL)XANTHINE; 1,3-DIPROPYL-8-CYCLOPENTYLXANTHINE; XANTHINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; FEMALE; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; ANESTHESIA; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; HEART MUSCLE ISCHEMIA; METABOLISM; RADIOASSAY; REPERFUSION INJURY;

ANESTHESIA; ANIMALS; DISEASE MODELS, ANIMAL; DOGS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; XANTHINES;

EID: 10744233575     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.057943     Document Type: Article

References (39)

1. ATP channels and ischemic preconditioning in dogs. Am J Physiol 264:H1327-H1336.
2. 2B receptor. Mol Pharmacol 52:846-860.
3. 6-(3-iodobenzyl)adenosine-5′-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res 80:800-809.
4. Balakrishnan VS, Coles GA, and Williams JD (1996) Effects of intravenous adenosine on renal function in healthy human subjects. Am J Physiol 271: F374-F381.
5. 1 adenosine receptor antagonist in the guinea pig heart and brain and in DDT1MF-2 cells. J Pharmacol Exp Ther 275:1167-1176.
6. Belloni FL, Belardinelh L, Halperin C, and Hintze TH (1989) An unusual receptor mediates adenosine-induced SA nodal bradycardia in dogs. Am J Physiol 256: H1553-H1564.
7. Bolli R (2000) The late phase of preconditioning. Circ Res 87:972-983.
8. 1 receptor-deficient mice. Am J Physiol 281:R1362-R1367.
9. Domenech RJ, Macho P, Velez D, Sanchez G, Liu X, and Dhalla N (1998) Tachycardia preconditions infarct size in dogs: role of adenosine and protein kinase C. Circulation 97:786-794.
10. Ely SW and Berne RM (1992) Protective effects of adenosine in myocardial ischemia. Circulation 85:893-904.
11. Forman MB, Vitola JV, Velasco CE, Murray JJ, Dubey RK, and Jackson EK (2000) Sustained reduction in myocardial reperfusion injury with an adenosine receptor antagonist: possible role of the neutrophil chemoattractant response. J Pharmacol Exp Ther 292:929-938.
12. 1 receptor antagonist with unique diuretic activity. J Pharmacol Exp Ther 286:1191-1196.
13. Goto M, Liu Y, Yang XM, Ardell JL, Cohen MV, and Downey JM (1995) Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 77:611-621.
14. 1-receptor antagonists in congestive heart failure. Drugs 61:1387-1393.
15. 1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105:1348-1353.
16. 1-adenosine receptor antagonist and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol 35:56-59.
17. Gross GJ and Auchampach JA (1992) Role of ATP dependent potassium channels in myocardial ischaemia. Cardiovasc Res 26:1011-1016.
18. Haessler R, Kuzume K, Wolff RA, Chien GL, Davis RF, and Van Winkle DM (1996) Adrenergic activation confers cardioprotection mediated by adenosine, but is not required for ischemic preconditioning. Coronary Artery Dis 7:305-314.
19. Holz FG and Steinhausen M (1987) Renovascular effects of adenosine receptor agonists. Renal Physiol 10:272-282.
20. 2B adenosine receptors. Biochem Pharmacol 61:657-663.
21. Kitakaze M, Minamino T, Funaya H, Node K, Shinozaki Y, Mori H, and Hori M (1997) Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart. Circulation 95:2108-2114.
22. Libert F, Parmentier M, Lefort A, Dinsart C, Van Sande J, Maenhaut C, Simons MJ, Dumont JE, and Vassart G (1989) Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science (Wash DC) 244:569-572.
23. Linden J (1982) Calculating the dissociation constant of an unlabeled compound from the concentration required to displace radiolabel binding by 50%. J Cyclic Nucleotide Res 8:163-172.
24. Marquardt DM (1963) An algorithm for least-squares estimation of nonlinear parameters. J Soc Indust Appl Math 11:431-441.
25. 2 adenosine receptor subtypes. Eur J Pharmacol 214:199-205.
26. Miki T, Cohen MV, and Downey JM (1998) Opioid receptor contributes to ischemic preconditioning through protein kinase C activation in rabbits. Mol Cell Biochem 186:3-12.
27. Nakano A, Cohen MV, and Downey JM (2000) Ischemic preconditioning: from basic mechanisms to clinical applications. Pharmacol Ther 86:263-275.
28. 1 adenosine receptor antagonists block ischemia-reperfusion injury of the heart. Circulation 94:II376-380.
29. 1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine. J Med Chem 40:1773-1778.
30. Schnermann J (2002) Adenosine mediates tubuloglomerular feedback. Am J Physiol 283:R276-R277; discussion R278-279.
31. Sun D, Samuelson LC, Yang T, Huang Y, Paliege A, Saunders T, Briggs J, and Schnermann J (2001) Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc Natl Acad Sci USA 98:9983-9988.
32. 1 receptor. Am J Physiol 265: F511-F519.
33. Thornton JD, Thornton CS, and Downey JM (1993) Effect of adenosine receptor blockade: preventing protective preconditioning depends on time of initiation. Am J Physiol 265:H504-H508.
34. 1 adenosine receptor antagonist, in rats and nonhuman primates. Drug Dev Res 58:486-492.
35. Todd J, Zhao ZQ, Williams MW, Sato H, Van Wylen DG, and Vinten-Johansen J (1996) Intravascular adenosine at reperfusion reduces infarct size and neutrophil adherence. Ann Thorac Surg 62:1364-1372.
36. 1 adenosine receptors. Two amino acids are responsible for species differences in ligand recognition. J Biol Chem 269:27900-27906.
37. Vinten-Johansen J, Thourani VH, Ronson RS, Jordan JE, Zhao ZQ, Nakamura M, Velez D, and Guyton RA (1999) Broad-spectrum cardioprotection with adenosine. Ann Thorac Surg 68:1942-1948.
38. 1 receptor antagonist. J Am Soc Nephrol 10:714-720.
39. 1 receptor mediated myocardial infarct size reduction by endogenous adenosine is exerted primarily during ischaemia. Cardiovasc Res 28:270-279.